Viz.ai, Inc.: Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)

Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM Viz.ai, a leader in AI-powered disease detection

Related Keywords

United States ,Dennis Riedl ,Chris Mansi ,Ariane Lovell ,Bristol Myers Squibb ,Suhas Krishna ,David Huneycutt ,Healthcare Tristar Centennial Medical Center ,Head Of Digital Health Product Management ,Drug Administration ,Announces Agreement ,Hypertrophic Cardiomyopathy ,Business Wire ,Tristar Centennial Medical Center ,Vice President ,Digital Health Product Management ,Bristol Myers ,Cardio Suite ,Intelligent Care Coordination Platform ,Viz Cardio Suite ,Viz Platform ,Announces ,Agreement ,Bristol ,Myers ,Squibb ,Nable ,Earlier ,Detection ,Management ,Suspected ,Ypertrophic ,Cardiomyopathy ,